| Next 10 |
Ad
SPPI News and Press Spectrum Pharmaceuticals Inc.
News | Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)
-
New York, New York--(Newsfile Corp. - December 14, 2022) - Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit. The lawsuit on behalf of Spectrum investors has been commenced in the the...
-
NEW YORK, NY / ACCESSWIRE / December 12, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ:SPPI) and reminds investors of the February 3, 2023 deadline to seek th...
-
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 7, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, i...
-
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network® Supportive Care Guidelines (NCCN Guidelines) in oncology ...
-
-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant -- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology the...
-
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), F45 Training Holdings, Inc. (NYSE: FXLV), PROG Holdings, Inc. (NYSE: PRG), and...
-
— Immediately de-prioritizes poziotinib program, accelerates cost reductions, including 75% reduction in R&D related workforce — — Spectrum to explore strategic alternatives for the poziotinib program, including partnerships and business development op...
-
NEW YORK, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against against GrafTech International Ltd. (NYSE: EAF), Cantaloupe, Inc. (NASDAQ: CTLP, OTCMKTS: CTLPP), Spectrum Pharmaceutic...
-
B Riley has downgraded Spectrum Pharmaceuticals ( NASDAQ: SPPI ) to neutral from buy citing uncertainty over the approval of poziotinib later this month and a challenging near-term pipeline catalyst profile. The firm also lowered its price target to $1 from $1.50 (~92...
-
Spectrum Pharmaceuticals, Inc. (SPPI) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Michael Grabow - Executive Vice President of Chief Business Officer Thomas Riga - President and Chief Executive Officer Francois J. Lebel - Ex...
Stock Information
Spectrum Pharmaceuticals Inc. Company Name:
SPPI Stock Symbol:
NASDAQ Market:
Spectrum Pharmaceuticals Inc. Website:
Ad
-
New York, New York--(Newsfile Corp. - December 14, 2022) - Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit. The lawsuit on behalf of Spectrum investors has been commenced in the the...
-
NEW YORK, NY / ACCESSWIRE / December 12, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ:SPPI) and reminds investors of the February 3, 2023 deadline to seek th...
-
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 7, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, i...